Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma

Novartis

Status and phase: Withdrawn; Phase 2; Phase 1

Conditions: Asthma

Treatments: Drug: QAX576; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT00598104

CQAX576A2103

Details and patient eligibility

About

This study will evaluate the safety and efficacy of QAX576 against asthma attacks in adults with moderate persistent allergic asthma

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• History of asthma attacks
• Taking inhaled corticosteroids
• Non-smoking

Exclusion criteria

• Women of child-bearing potential
• History of respiratory disease other than asthma
• History of severe allergy to food or drugs
• Previous use of monoclonal antibodies
• Very low or high body weight

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

0 participants in 2 patient groups, including a placebo group

1

Experimental group

Treatment:

Drug: QAX576

2

Placebo Comparator group

Treatment:

Drug: Placebo